Heather H. Cheng, MD, PhD, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and director, Prostate Cancer Genetics Clinic, Seattle Cancer Care Alliance, discusses the goals of the ongoing GENTleMEN trial (NCT03503097) in prostate cancer.

The GENTleMEN trial, which has been open since 2007, is a web-based study where men answer questions about their family history, as well as their knowledge and distress of genetic testing. The questionnaire takes approximately 40 minutes for most patients, and if they meet qualifications, they are mailed a saliva kit, explains Cheng. If patients have a relevant mutation, a genetic counselor will discuss the results either by phone or in person. 

 showed that the prevalence of inherited cancer risk mutations in DNA repair genes was approximately 12% in the metastatic prostate cancer setting, according to Cheng. Subsequently, the National Comprehensive Cancer Network guidelines specified that all men with metastatic prostate cancer should be considered for genetic testing, added Cheng.

To date, data from the GENTleMEN suggests that the prevalence for this population for genetic testing is approximately 10%, says Cheng. Despite the rise in genetic testing, ancillary questions such as delivery method and patient satisfaction still need to be addressed if online genetic counseling is to be adopted into clinical practice, concludes Cheng.

Videos

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

Heather H. Cheng, MD, PhD, associate professor of medical oncology, University of Washington School of Medicine, director, Prostate Cancer Genetics Clinic, Seattle Cancer Care Alliance, discusses considerations for molecular testing in prostate cancer.

Typically, patients fall into 3 categories: men with metastatic prostate cancer, men whose cancer was detected early, and men who are at risk of developing prostate cancer based on genetic risk factors, explains Cheng.

Patients with metastatic disease may be more concerned with available treatment options than molecular testing as their disease requires immediate intervention, says Cheng.

Conversely, patients who are at a high risk of developing prostate cancer may want to focus on relaying relevant genetic information to allow their family members to take precautionary steps regarding their own health.

Patients with localized disease may want to discuss therapy options as well as family implications upon diagnosis, explains Cheng.

Enrollment in clinical trials and early identification of patients with high risk factors such as BRCA2 mutations is necessary to reduce the number of patients who develop metastatic disease, concludes Cheng.

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Heather H. Cheng, MD, PhD

Articles

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

Dr. Cheng on Molecular Testing Considerations in Prostate Cancer